Development of Cancer Drugs for Use in Novel Combination - Determining the Contribution of the Individual Drugs’ Effects: Draft Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
July 17, 2025
July 16, 2025
bd360fda-a944-4c60-9940-379a8b849635
Related Documents
Tissue Agnostic Drug Development in Oncology: Draft Guidance for Industry
Guidance DocumentOctober 17, 2022Office of the Commissioner
Considerations for Generating Clinical Evidence from Oncology Multiregional Clinical Development Programs
Guidance DocumentSeptember 16, 2024Office of the Commissioner
Combined Food and Drug Administration and Sponsor Oncologic Drugs Advisory Committee Briefing Document
Guidance DocumentDecember 27, 2024Office of the Commissioner
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox